资金近期持续流入中药板块，中药ETF(159647)今日净申购350万份，连续23天获净流入。 消息面上，2025年一季度，中药行业营收同比下降8%，利润同比下降4%。二季度营收同比下降2%，利 润同比增长7%。虽然收入端仍有下滑，但降幅已明显收窄，利润端表现优于收入端，显示出一定的韧 性。 截至2025年10月21日 15:00，中证中药指数(930641)上涨0.21%，成分股华神科技(000790)上涨3.64%， 粤万年青(301111)上涨2.66%，太龙药业(600222)上涨2.48%，以岭药业(002603)上涨2.05%，陇神戎发 (300534)上涨2.01%。中药ETF(159647)上涨0.10%，最新价报1.01元，今日净申购350万份，连续23天获 净流入。 机构认为，当下关注四大核心因素： 中药ETF紧密跟踪中证中药指数，中证中药指数选取涉及中药生产与销售等业务的上市公司证券作为样 本，以反映中药概念类上市公司的整体表现。 1、政策端：中成药集采与基药目录调整 集采：已推进三轮，第三轮平均降幅63%，但对上市公司大品种影响有限； 基药目录：上一版为2018年发布，已超6年未更新， ...

Group 1 - The core viewpoint of the news is the strong performance of the Traditional Chinese Medicine (TCM) sector, highlighted by the rise of the Zhongzheng TCM Index and its constituent stocks, driven by new regulations on the labeling of TCM decoction pieces [1][2] - As of July 30, 2025, the Zhongzheng TCM Index increased by 1.80%, with notable gains from stocks such as Da Ren Tang (up 4.85%), Yunnan Baiyao (up 3.31%), and Dong'e Ejiao (up 3.10%) [1] - The new labeling regulations for TCM decoction pieces, effective from August 1, 2025, require detailed information on product attributes, including shelf life, which is expected to impact the market positively [1] Group 2 - The Zhongzheng TCM Index (930641) includes companies involved in the production and sales of TCM, reflecting the overall performance of TCM-related listed companies [2] - As of June 30, 2025, the top ten weighted stocks in the Zhongzheng TCM Index accounted for 55.96% of the index, with key players including Pian Zai Huang, Yunnan Baiyao, and Tong Ren Tang [2] - The TCM ETF (159647) closely tracks the Zhongzheng TCM Index, indicating a strong correlation between the ETF's performance and the underlying index [3]